Fig. 8: KDM5B suppresses ATF3 expression through histone demethylation of the Atf3 promoter. | Experimental & Molecular Medicine

Fig. 8: KDM5B suppresses ATF3 expression through histone demethylation of the Atf3 promoter.

From: Loss of KDM5B ameliorates pathological cardiac fibrosis and dysfunction by epigenetically enhancing ATF3 expression

Fig. 8

a ChIP analysis of KDM5B enrichment levels at the Atf3 promoter in WT cardiac fibroblasts treated with TGF-β (10 ng/ml) or the control PBS (Ctrl) for 24 h. n = 6 per group. b–d Immunoblot analysis of H3K4me2 and H3K4me3 levels in cardiac fibroblasts with KDM5B deficiency (b), KDM5B knockdown (c) or GSK467 treatment (d) and the corresponding control cardiac fibroblasts (b–d) stimulated with TGF-β (10 ng/ml) for the indicated times. Similar results were obtained from three independent experiments. e, f ChIP analysis of H3K4me2 (e) or H3K4me3 (f) levels at the Atf3 promoter of WT cardiac fibroblasts treated with TGF-β (10 ng/ml) or control PBS (Ctrl) for 24 h. n = 6 per group. g, h ChIP analysis of H3K4me2 (g) or H3K4me3 (h) levels at the Atf3 promoter of KDM5B-deficient (KO) or WT cardiac fibroblasts stimulated with TGF-β (10 ng/ml) for 24 h. n = 6 per group. *p < 0.05, ***p < 0.001. Two-way ANOVA (a, e–h) was performed.

Back to article page